# Population germline screening for hereditary cancer genes with cascade testing

Source: https://onco.cc/ideas/idea-moon-population-germline-screening/  
OnCo record `idea-moon-population-germline-screening` (Idea). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Most people carrying a high-risk cancer gene do not know it until someone in the family gets cancer. Offer testing to all adults so carriers can be protected before that happens.

## Summary

Family-history-based testing misses about half of BRCA and Lynch carriers. Population screening pilots (Ashkenazi BRCA programmes, Geisinger MyCode, Healthy Nevada) identify carriers efficiently and studies suggest cost-effectiveness at current sequencing prices. The proposal is national population screening for a defined panel of actionable hereditary cancer genes offered to all adults at a set age, with automated cascade testing offers to relatives, standardised risk-reducing pathways (enhanced surveillance, chemoprevention, risk-reducing surgery) and long-term outcome tracking.

## Fields

- Kind: Idea
- Last checked: 2026-09-08
- Hypothesis: Population screening identifies at least twice as many carriers as family-history testing and reduces incidence of advanced BRCA- and Lynch-associated cancers among carriers by half within a decade.
- Rationale: Carrier identification followed by proven risk reduction prevents cancers rather than treating them, and sequencing cost is now trivial relative to a single cancer treatment.
- Proposed test: Regional programme with randomised age-cohort rollout; endpoints carrier detection rate, uptake of risk reduction and stage at diagnosis of hereditary cancers versus unscreened regions.
- Maturity: being-tested-at-scale
- Actor: policy

## Sources

- Bottleneck evidence (Inherited risk is mostly unidentified): Childers et al., National estimates of genetic testing in women with breast or ovarian cancer (JCO 2017): https://doi.org/10.1200/JCO.2017.73.6314

## Connected records

- cancers: [Colorectal cancer](https://onco.cc/cancers/colorectal/), [HR-positive / HER2-negative breast cancer](https://onco.cc/cancers/breast-hr-positive/), [Ovarian cancer](https://onco.cc/cancers/ovarian/)
- technologies: [Chemoprevention & risk-reducing surgery](https://onco.cc/technologies/chemoprevention/), [Germline (hereditary) testing](https://onco.cc/technologies/germline-testing/)
- targets: [BRCA1 / BRCA2 (HRD)](https://onco.cc/targets/brca/)
- terms: [Germline vs somatic mutations](https://onco.cc/terms/germline-vs-somatic/)
- bottlenecks: [Inherited risk is mostly unidentified](https://onco.cc/bottlenecks/b-hereditary-risk/), [Prevention we already have is not deployed](https://onco.cc/bottlenecks/b-prevention-adoption/)
- key papers: [National Estimates of Genetic Testing in Women With a History of Breast or Ovarian Cancer](https://onco.cc/key-papers/paper-childers-j-clin-oncol/), [PROSE consortium: preventive surgery lowers cancer and death in BRCA1 and BRCA2 carriers](https://onco.cc/key-papers/paper-brca-risk-reducing-surgery-jama-2010/)
- roadmaps: [Cancer prevention roadmap: tobacco control and vaccines → biomarker-guided chemoprevention → interception in carriers](https://onco.cc/roadmaps/prevention-roadmap/)

---
JSON: https://onco.cc/api/v1/entities/idea-moon-population-germline-screening.json